Oncorus (Oncorus) 5-Year Yield-on-Cost % : 0.00 (As of May. 15, 2024)

View and export this data going back to 2020. Start your Free Trial

What is Oncorus 5-Year Yield-on-Cost %?

Oncorus's yield on cost for the quarter that ended in Mar. 2023 was 0.00.

The historical rank and industry rank for Oncorus's 5-Year Yield-on-Cost % or its related term are showing as below:

ONCR's 5-Year Yield-on-Cost % is not ranked ^*
in the Biotechnology industry.
Industry Median: 1.815
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Competitive Comparison of Oncorus's 5-Year Yield-on-Cost %

For the Biotechnology subindustry, Oncorus's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Oncorus's 5-Year Yield-on-Cost % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oncorus's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Oncorus's 5-Year Yield-on-Cost % falls into.

Oncorus 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Oncorus is calculated as

Yield-on-Cost

Dividend Yield %

Dividend Growth Rate)^5

Oncorus (OTCPK:ONCR) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.

Oncorus 5-Year Yield-on-Cost % Related Terms

Thank you for viewing the detailed overview of Oncorus's 5-Year Yield-on-Cost % provided by GuruFocus.com. Please click on the following links to see related term pages.

Oncorus (Oncorus) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncorus Inc (OTCPK:ONCR) » Definitions » 5-Year Yield-on-Cost %

Comparable Companies

Traded in Other Exchanges

N/A

Address

4 Corporate Drive, Andover, MA, USA, 01810

Website

https://www.oncorus.com

Oncorus Inc is a preclinical-stage biopharmaceutical company focused on the intravenous administration of self-amplifying RNA to transform outcomes for cancer patients. The company is in the process of developing intratumorally and intravenously administered product candidates designed to selectively attack and kill tumor cells and stimulate multiple arms of the immune system against tumors. Its pipeline product includes ONCR-021 and ONCR-788 which are based on coxsackievirus A21 or CVA21, and Seneca Valley Virus, or SVV, respectively.

Executives

Brian J. Shea	officer: Interim CEO	C/O ONCORUS, INC., 4 CORPORATE DRIVE, ANDOVER MA 01810
Alexander Nolte	officer: Interim CFO	35 GATEHOUSE DRIVE, BUILDING D, FLOOR 3, WALTHAM MA 02451
James E Flynn	director, 10 percent owner, other: *Possible Member of 10% Group	780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Douglas Fambrough	director	C/O DICERNA PHARMACEUTICALS, INC., 75 HAYDEN AVENUE, LEXINGTON MA 02421
Rick Wanstall	officer: CFO and Treasurer	C/O AILERON THERAPEUTICS, INC., 490 ARSENAL WAY, WATERTOWN MA 02472
Stephen Harbin	officer: COO and Chief of Staff	C/O ONCORUS, INC., 50 HAMPSHIRE STREET, SUITE 401, CAMBRIDGE MA 02139
Barbara Yanni	director	1018 W. 8TH AVENUE, SUITE A, KING OF PRUSSIA PA 19406
Eric Rubin	director	C/O ONCORUS, INC., 50 HAMPSHIRE STREET, SUITE 401, CAMBRIDGE MA 02139
Christophe Queva	officer: CSO and SVP, Research	C/O ONCORUS, INC., 50 HAMPSHIRE STREET, SUITE 401, CAMBRIDGE MA 02139
Scott A Canute	director	FLEXION THERAPEUTICS, INC., 10 MALL ROAD, SUITE 301, BURLINGTON MA 01803
Mpm Bioventures 2014, L.p.	10 percent owner	C/O MPM ASSET MANAGEMENT LLC, 450 KENDALL STREET, CAMBRIDGE MA 02142
Luke Evnin	director, 10 percent owner	THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH STREET, BOSTON MA 02116
Oncology Impact Fund (cayman) Management L.p.	10 percent owner	450 KENDALL STREET, CAMBRIDGE MA 02142
Mpm Asset Management Investors Sunstates Fund Llc	10 percent owner	450 KENDALL STREET, CAMBRIDGE MA 02142
Ansbert Gadicke	10 percent owner	THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH FLOOR, BOSTON MA 02116